carbidopa,Levodopa
NeuroDerm
['carbidopa']
a new subcutaneous system for infusing levodopa-carbidopa continuously over 24 hours to control #parkinsonsdisease met its primary and secondary endpoints in a double-blind, double-dummy phase 3 multicenter trial. #aanam #aan2023 
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.